You just read:

Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

News provided by

Theravance Biopharma, Inc.

Oct 20, 2016, 06:55 ET